Skip to main content

Advertisement

Log in

Exploring the chemotherapeutic potential and therapeutic insight of phloretin against human malignancies: a systematic review

  • Published:
Phytochemistry Reviews Aims and scope Submit manuscript

Abstract

The search of alternative therapeutic agents for the use  of cancer patients has dramatically expanded. Natural products are especially in focus since their structures already function in nature and are more likely to be potent with fewer side effects. Phloretin is a natural product that has been studied for a wide variety of pharmacological actions against human malignancies. This systematic review aims to present up-to-date critical and comprehensive information on the anti-cancer ability of Phloretin with all associated molecular and cellular mechanisms in various forms of cancers. Data retrieved according to PRISMA guidelines from Science Direct, PubMed, and Scopus searching servers by using keywords including Phloretin, cancer name, synergistic, resistance and Pharmacokinetics property was analyzed via some in silico tools. This systematic review comprised 127 articles from different types of study, where Phloretin is hypothesized to be effective against 20 various forms of cancer. Phloretin has been found to inhibit cancer initiation and progression by modulating many imbalanced signalling pathways, including apoptosis, autophagy, necrosis, metastasis, angiogenesis, cell proliferation, glucose absorption, oxidative stress, inflammation, DNA damage, and many other pathways. This wide range of activity may be due to the structural targeting of numerous proteins including, Bcl-2, Bax, Bak, Bad, caspase, cyclins (B1, D1, E) and CDKs (4, 6,7) p18, p21, p27, p53, MMP-2, MMP- 8, MMP-9, Wnt/-catenin, PARP, TNF-α, NF-κB, IκB kinase, IL-1β, TNF-α, phospho-Akt, phosphor-p65, NF-κB, PI3K/Akt, MAPK/ERK, p-mTOR. The introduction of nano-technology-based strategies can improve the efficacy of Phloretin for cancer treatment. Existing evidence shows that Phloretin has synergistic effects with other natural compounds and conventional drugs, and this mechanism assists in reversing the resistance of anticancer drugs by regulating resistance-related proteins. However, Phloretin possesses favorable pharmacokinetic properties with  low toxicity in the human body by in silico methods. Therefore, Phloretin could be a potential anti-cancer drug against numerous cancer treatment by mitigating it's toxic effect and enhancing efficacy using nano-technology-based strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Abbreviations

Bcl-2:

B-cell leukemia 2

Bax:

Bcl-2-Associated X protein

PI3K:

Phosphoinositide 3-kinase

Akt:

Ak strain transforming

mTOR:

Mammalian target of rapamycin

MMP9 :

Matrix metalloproteinase 9

GLUT:

Glucose transporters

ULK1 :

Unc-51 like autophagy activating kinase

ERK1/2:

Extracellular signal-regulated kinase 1/2

TPA :

Tissue plasminogen activator

LC3B :

Light chain 3B

BCL-XL :

B-cell lymphoma-extra large

XIAP :

X-linked inhibitor of apoptosis protein

VEGF :

Vascular endothelial growth factor

MTT :

3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide

CAT :

Chloramphenicol acetyltransferase

SOD :

Superoxide dismutase

NF-B :

Nuclear factor-B

Mac-1 :

Macrophage 1 antigen

PEP :

Phosphoenolpyruvate

GraB :

Granzyme B

c-Myc :

Cellular Myc

ROS :

Reactive oxygen species

HCC :

Hepatocellular carcinoma

SHP-1 :

Src homology region 2 domain-containing phosphatase-1

STAT3 :

Signal transducer and activator of transcription 3

pERK :

Protein kinase RNA-like endoplasmic reticulum kinase

VEGFR :

Vascular endothelial growth factor receptor

MAPK :

Mitogen-activated protein kinase

CXCL12 :

C-X-C motif chemokine ligand 12

CXCR4 :

C-X-C motif chemokine receptor 4

TLR1 :

Toll-like receptor 1

TLR2:

Toll-like receptor 2

TNF-α :

Tumor necrosis factor-alpha

NOD :

Nucleotide-binding oligomerization domain

NLRP3:

Nucleotide-binding domain (NOD)-like receptor protein 3

CDK4 :

Cyclin-dependent kinase 4

CDK6 :

Cyclin-dependent kinase 6

BAK :

Bcl-2 homologous antagonist/killer

PARP :

Poly-ADP ribose polymerase

HIF1 :

Hypoxia-inducible factor-1

HKII :

Hexokinase 2

PFKFB3 :

6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isozyme 3

PDHK1 :

Pyruvate dehydrogenase kinase 1

LDH :

Lactate dehydrogenase

Pink1 :

PTEN-induced kinase 1

GSH:

Glutathione

NSCLC :

Non-small cell lung cancer

JNK :

C-Jun N-terminal kinase

TRX:

Thioredoxin

TXNIP :

Thioredoxin interacting protein

2-NBDLG :

2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amino]-2-deoxy-D-glucose

PKC:

Protein kinase C

Myt1 :

Myelin transcription factor 1

cdc2:

Cyclin-dependent kinase 2

HSP70:

70 Kilodalton heat shock protein

IL-6:

Interleukin-6

MRP:

Multi-drug resistance associated protein 1

BCRP:

Breast cancer resistance protein

MDR:

Multi-drug resistance

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Abdullah Al Mamun.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sohel, M., Nity, N.U., Sarker, M.R. et al. Exploring the chemotherapeutic potential and therapeutic insight of phloretin against human malignancies: a systematic review. Phytochem Rev (2024). https://doi.org/10.1007/s11101-024-09938-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11101-024-09938-8

Keywords

Navigation